A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical TrialsFirst published 28/09/2021 Last updated 30/10/2024 EU PAS number: EUPAS43115StudyFinalised